Xlife Sciences AG: Exit of a project company
23.12.2020 13:14:00 EET | Business Wire | Press release
Xlife Sciences AG has successfully realized its 60% stake of the project company Araxa Biosciences GmbH in Veraxa Biotech AG (formerly Velaxa AG). This transaction has a total value of more than 20 million euros and Xlife Sciences AG will now become a part of the Board of Directors of Veraxa as a minority shareholder. Veraxa Biotech AG is positioned as a leading provider in the identification and development of functional antibodies and drug conjugates.
Xlife Sciences AG will exceed its earnings expectations for 2020 with this first completed transaction since founding of the company. Araxa Biosciences GmbH was a spin-off from the European Molecular Biology Laboratory EMBL in Heidelberg and was founded by Xlife Sciences AG in summer 2019. Over the past one and a half years, Xlife has invested nearly one million euros in the company. In collaboration with various industry experts, the technological development of Araxa has been successfully advanced.
About Veraxa Biotech AG
Veraxa Biotech AG identifies and develops functional antibodies and antibody drug conjugates (ADC's) for the bio- and pharmaceutical industry in exchange for license agreements. The aim is to accelerate the safe development of medical drugs, as well as to enhance the probabilities of drug developments in various clinical phases. Using this technology, Veraxa Biotech AG can screen millions of b-cells in one single step in less than 48 hours for functional antibodies and additionally also modify them with drug conjugates.
About Xlife Sciences AG
Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage. For more information, please visit: www.xlifesciences.ch
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201223005137/en/
Contact information
For media inquiries:
Oliver R. Baumann
CEO Xlife Sciences AG
Tel. +41 44 385 84 60
oliver.baumann@xlifesciences.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Saildrone Unveils Spectre, a New Class of High-Speed Unmanned Surface Vessel for Naval Operations20.4.2026 15:00:00 EEST | Press release
Saildrone, the world leader and most experienced operator of unmanned surface vehicles (USVs), today released the design of the Saildrone Spectre, the culmination of two years of intense design work, leveraging over 10 years of operational USV experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420620393/en/ Two Saildrone Spectre variants are built around different mission needs: Spectre Silent Endurance (right) uses wing assist for extreme endurance and silent propulsion. Spectre Stealth Strike (left) meets all mUSV requirements. At 52 meters (170 feet) long, weighing 250 tonnes, and capable of up to 30 knots, Spectre is the largest, fastest, and most capable Saildrone platform to date. Spectre is optimized for anti-submarine warfare (ASW) operations, a mission set that demands extreme endurance and an ultra-quiet acoustic signature. Spectre achieves this by leveraging the proven endurance, reliability, and silent
Saildrone Unveils Spectre, a New Class of High-Speed Unmanned Surface Vessel for Naval Operations20.4.2026 15:00:00 EEST | Press release
Saildrone, the world leader and most experienced operator of unmanned surface vehicles (USVs), today released the design of the Saildrone Spectre, the culmination of two years of intense design work, leveraging over 10 years of operational USV experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420620393/en/ Two Saildrone Spectre variants are built around different mission needs: Spectre Silent Endurance (right) uses wing assist for extreme endurance and silent propulsion. Spectre Stealth Strike (left) meets all mUSV requirements. At 52 meters (170 feet) long, weighing 250 tonnes, and capable of up to 30 knots, Spectre is the largest, fastest, and most capable Saildrone platform to date. Spectre is optimized for anti-submarine warfare (ASW) operations, a mission set that demands extreme endurance and an ultra-quiet acoustic signature. Spectre achieves this by leveraging the proven endurance, reliability, and silent
Ushio Industry & Entertainment Appoints Takuya Matsumoto as President & CEO and Outlines Strategic Direction for the Next Phase20.4.2026 13:32:00 EEST | Press release
Ushio Industry & Entertainment (Ushio INE GmbH) announces the appointment of Takuya Matsumoto as President and Chief Executive Officer, marking a key milestone in the evolution of the business and its integration within the Ushio Group. With more than 20 years of experience across sales, new business development, and global operations, Takuya Matsumoto brings deep industry expertise and a strong leadership track record within Ushio. Most recently, he served as General Manager of the Global Business Unit, where he played a pivotal role in advancing global growth initiatives. A Clear Vision: A strong heritage with a forward-looking vision focused on innovation, operational excellence, and customer value Under Takuya Matsumoto’s leadership, Ushio INE will continue to build on its strong legacy while advancing its mission to deliver high-performance, high-quality lighting solutions across industrial and entertainment markets worldwide. “Our mission is to continuously deliver essential ligh
Ushio Industry & Entertainment Appoints Takuya Matsumoto as President & CEO and Outlines Strategic Direction for the Next Phase20.4.2026 13:32:00 EEST | Press release
Ushio Industry & Entertainment (Ushio INE GmbH) announces the appointment of Takuya Matsumoto as President and Chief Executive Officer, marking a key milestone in the evolution of the business and its integration within the Ushio Group. With more than 20 years of experience across sales, new business development, and global operations, Takuya Matsumoto brings deep industry expertise and a strong leadership track record within Ushio. Most recently, he served as General Manager of the Global Business Unit, where he played a pivotal role in advancing global growth initiatives. A Clear Vision: A strong heritage with a forward-looking vision focused on innovation, operational excellence, and customer value Under Takuya Matsumoto’s leadership, Ushio INE will continue to build on its strong legacy while advancing its mission to deliver high-performance, high-quality lighting solutions across industrial and entertainment markets worldwide. “Our mission is to continuously deliver essential ligh
Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 202620.4.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that CEO Kabir Nath will participate in a panel entitled “Clinical Risk, Regulatory Reality and the Path to Scale” at the Needham Virtual Psychedelics Forum on April 27, 2026, at 11am-12pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable response
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom